Teva Announces Changes to Executive Management Team
28 Setembro 2023 - 5:05PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced changes to its leadership team. Sven Dethlefs, Executive
Vice President, North America Commercial, will leave Teva on
November 17, 2023, and Christine (Chris) Fox, who most recently
served as Global President, Gene Therapies at Novartis will be the
new head of Teva’s U.S. Commercial Business. “On behalf of the Teva
Board of Directors and our executive management team, I want to
thank Sven for his many contributions to Teva during his 15 years
with the company,” said Richard Francis, Teva’s President, and
Chief Executive Officer, “I am pleased to announce the appointment
of Chris Fox to this critical role. Chris is a heralded
pharmaceutical executive with extensive experience growing and
overseeing complex business units and regional operations
throughout the world. I have every confidence that Chris will bring
great strength to Teva and be pivotal to our success.”
Biography: Christine Fox
Christine (Chris) Fox comes to Teva as Executive Vice President,
U.S. Commercial Business from her role at Novartis Gene Therapies
where she started as President in December 2021. Prior to this
role, Chris was vice president and general manager for the Bone,
Cardiometabolic and Nephrology business for Amgen. She also served
as the general manager of the company’s United Kingdom and Ireland
affiliate. Earlier in her career, she also held leadership
positions at Merck, Takeda, and several startups.
Chris brings more than 30 years of healthcare industry
experience with leadership roles in sales, marketing, and
commercial operations, responsible for teams ranging from 2500+
associates to small, nimble consulting teams. She has a deep
understanding of issues affecting the pharmaceutical and biotech
sectors, as well as expertise across a range of therapy areas.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
innovative medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of innovative and
biopharmaceutical products. Learn more at www.tevapharm.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance, or achievements to differ significantly from
that expressed or implied by such forward-looking statements. You
can identify these forward-looking statements by the use of words
such as “should,” “expect,” “anticipate,” “estimate,” “target,”
“may,” “project,” “guidance,” “intend,” “plan,” “believe” and other
words and terms of similar meaning and expression in connection
with any discussion of future operating or financial performance.
Important factors that could cause or contribute to such
differences include risks relating to: our business and operations
in general, including our ability to attract, hire, integrate and
retain highly skilled personnel; our ability to successfully
compete in the marketplace; our substantial indebtedness;
compliance, regulatory and litigation matters; other financial and
economic risks; and other factors discussed in this press release,
in our quarterly report on Form 10-Q for the second quarter of
2023, and in our Annual Report on Form 10-K for the year ended
December 31, 2022, including in the sections captioned "Risk
Factors” and “Forward Looking Statements.” Forward-looking
statements speak only as of the date on which they are made, and we
assume no obligation to update or revise any forward-looking
statements or other information contained herein, whether as a
result of new information, future events or otherwise. You are
cautioned not to put undue reliance on these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230928260229/en/
IR Contacts United States Ran Meir (267) 468-4475
Sanjeev Sharma (93) 524-1908
PR Contacts United States Kelley Dougherty (973)
658-0237 Yonatan Beker (973) 2647378
Teva Pharmaceutical Indu... (NYSE:TEVA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024